Citations

Clear

3216 citation(s) found for "Zhang, Y Q".

APOE, ABCA7 , and RASGEF1C are associated with earlier onset of amyloid deposition from more than 4000 harmonized positron emission tomography images
Castellano, Tonnar , Wang, Ting Chen, Nolan, Emma , Wu, Yiyang , Clifton, Michelle, Janve, Vaibhav A. , Durant, Alaina, Regelson, Alexis, Cody, Karly Alex , Jagust, William, Albert, Marilyn , Resnick, Susan M. , Mayeux, Richard, Initiative, Alzheimer's Disease Neuroimaging, Bennett, David A. , Jager, Philip L. De , Mormino, Elizabeth C. , Koran, Mary Ellen I. , Wang, Ting‐Chen , Bennett, David A. , Koran, Mary Ellen , Cody, Karly A , Wang, Ting Chen, Zhang, Mengna , Harrison, Theresa M. , Engelman, Corinne D. , Johnson, Sterling C. , Sperling, Reisa Anne , Bilgel, Murat , Saykin, Andrew J. , Vardarajan, Badri Narayan , Mayeux, Richard , Initiative, Alzheimer's Disease Neuroimaging, Betthauser, Tobey J. , Schneider, Julie A. , Menon, Vilas , Tosun, Duygu , Archer, Derek B. , Dumitrescu, Logan , Hohman, Timothy J.

Mayo Clinic

Alzheimer's & Dementia | December 13, 2025 | Volume: 21 | Issue: 12 | Pages: No page available

10.1002/alz.71006 | PMID 41388821 Get It

Abstract INTRODUCTION New methods estimate amyloid positivity onset age (EAOA) from amyloid positron emission tomography (PET). We explore the genetics of EAOA to identify molecular factors underlying the earliest Alzheimer's disease (AD) changes. METHODS Harmonized amyloid PET data from 4216 participants were used in genome‐wide survival, tissue‐specific gene expression, and genetic covariance analyses of EAOA. RESULTS Variants in apolipoprotein E ( APOE ), ABCA7 , and RASGEF1C associated with earlier EAOA. APOE ε4/ε4 and ε3/ε4 converted 6.3 and 5 years earlier than ε3/ε3, respectively. ε2 was protective against earlier EAOA. rs4147929, an expression quantitative trait locus for ABCA7 , associated with a 4 year earlier EAOA. This variant was associated with lower brain expression of ABCA7 , which was associated with increased amyloid pathology at autopsy. Multiple immune‐related diseases shared genetic covariance with EAOA. DISCUSSION APOE , ABCA7 , and RASGEF1C associated with earlier EAOA, with supporting evidence from tissue‐specific expression analyses, offering insights into intervenable targets at early stages of AD. Highlights Novel methods estimate how long ago a patient converted to amyloid positivity. Estimating this amyloid clock allows us to determine the onset of the earliest Alzheimer's disease changes. We evaluated what genes influence when someone converts to amyloid positivity. Apolipoprotein E ( APOE ) , ABCA7 , and RASGEF1C associated with earlier age of amyloid positivity. Genetic results were supported by tissue‐specific expression analyses.
Quantitative Measures of Time to Loss of 15% Vital Capacity and Survival Extension in Slowly Progressive Amyotrophic Lateral Sclerosis (ALS) Patients Treated with the Immune Regulator NP001 Suggests an Immunopathogenic Subset of ALS
Goyal, Namita , Wiedau, Martina, Kasarskis, Edward J. , Forrest, B. D. , Zhang, Rongzhen , Bracci, Paige M. , Davis, Matthew W., Azhir, Ari, McGrath, Michael S. , Goyal, Namita A , Oskarsson, Björn E, Forrest, Bruce D , Bracci, Paige M. , McGrath, Michael S , Andrews, Jinsy , Oskarsson, Björn , Wiedau‐Pazos, Martina , Davis, Matthew W.

Mayo Clinic

Biomedicines | December 12, 2025 | Volume: 13 | Issue: 12 | Pages: 3060

10.3390/biomedicines13123060 | PMID 41463070 Get It

Background/Objectives: Overall survival in patients with amyotrophic lateral sclerosis (ALS) is linked to the rate of predicted respiratory vital capacity (PVC) loss. The objective of this study was to test whether changes in quantitative PVC measures over time linked to survival would define an immunopathogenic subset of ALS responsive to NP001, a regulator of innate immunity. Methods: In a retrospective study, data from intent-to-treat (ITT) population of two phase 2 trials of NP001 were evaluated for over time changes in PVC, time-to-event (TTE) loss of 15% PVC and PVC change from baseline, as linked to survival outcomes in patients treated with NP001 vs placebo. Results: Treatment with NP001 was associated with a significantly lower risk compared to placebo in the loss of 15% PVC over six months (p = 0.01; HR = 0.60, 95% CI: 0.39, 0.90). Data from the two trials were subsequently divided by a disease progression rate (DPR) value of 0.50 units of ALSFRS-R score lost per month for analysis of slow vs. rapid disease. In ALS patients with slowly progressive disease (DPR < 0.50), TTE PVC changes from baseline were slowed (p < 0.0005) and overall survival extended significantly (18.5 months) in NP001-treated vs. placebo groups. The rapidly progressive ALS patients (DPR ≥ 0.50) treated with NP001 showed no significant difference in PVC change or survival from the placebo group. Conclusions: These hypothesis-generating observations suggest that inflammation might play a significant role in the loss of respiratory function in a major subset of ALS patients.
PrevCardioOncAI: Machine Learning Algorithms for Predicting Cardiovascular Disease in Cancer Survivors
Brown, Sherry‐Ann , Fang, Michelle , Sparapani, Rodney , Osinski, Kristen , Taylor, Bradley , Yu, Duo , Blessing, Jeffrey, Shah, Rushabh , Collier, Patrick , Bagherimohamadipour, Mehri , Zhang, Jun , Kothari, Anai N. , Rickards, John , Otto, Cameron, Sanchez, Zanele, Arruda‐Olson, Adelaide M. , Cheng, Yee Chung , Fang, Michelle Z , Osinski, Kristen , Taylor, Bradley , Shah, Rushabh , Collier, Patrick , BagheriMohamadiPour, Mehri , Kothari, Anai , Echefu, Gift , Rickards, John , Olson, Jessica , Arruda-Olson, Adelaide, Cheng, Yee Chung , Cheng, Feixiong , Zhou, Yadi

Mayo Clinic

Journal of the American Heart Association | December 11, 2025 | Volume: 14 | Issue: 24 | Pages: No page available

10.1161/jaha.123.030363 | PMID 41378455 Get It

Background Cardiovascular disease (CVD) is a leading cause of death in cancer survivors. Predicting CVD risk in this population remains challenging. Risk prediction models that use machine learning algorithms could provide an objective method for accurate risk prediction to facilitate the prevention and management of CVD in cancer survivors. We evaluated previously tested machine learning algorithms and logistic regression (regularized by machine learning methods), in addition to testing and validating newer, more complex machine learning algorithms, for CVD prediction in cancer survivors. Methods This multicenter study used a database of 3835 multiracial cancer survivors with 89 clinical, laboratory, and echocardiographic features over 20 years. Models were trained using repeated random and time‐split samples and tested on a separate cohort of 329 patients. Model performance was assessed using the area under the receiver operating characteristic curve. Results Regularized logistic regression achieved an area under the receiver operating characteristic curve of 0.845 (heart failure), 0.783 (atrial fibrillation), 0.792 (coronary artery disease), and 0.806 (composite CVD). These are comparable to 0.837 and 0.848 for heart failure, using Bayesian additive regression tree and random forest as more advanced machine learning models, respectively. De novo composite CVD (post‐cancer diagnosis) was also predicted with an area under the receiver operating characteristic curve of 0.826 using regularized logistic regression, compared with 0.735 and 0.802 using decision tree and random forest, respectively. Conclusions Regularized logistic regression and advanced machine learning models demonstrated similar predictive performance, with institutional transferability. These tools may support risk stratification and prevention strategies in cardio‐oncology using longitudinal data. Registration URL: https://www.clinicaltrials.gov ; Unique identifier: NCT05377320.
Magnetic resonance elastography characterization of meningioma mechanical properties for improved neurosurgical planning and resection: a prospective cohort study
Bai, Shengjun, Zeng, Yu , Hong, Yang , Han, Shuai , Zhang, Tianhe, Guo, Mingzhe, Wu, Jianqi , Sheng, Yiyang, Wu, Anhua , Zheng, Keni, Huston Iii, John, Jiao, Niandong, Cheng, Wen , Bai, Shengjun, Zheng, Keni , Zhang, Tianhe, Guo, Mingzhe, Liu, Tianqi , Manduca, Armando , Huston, John , Wu, Qi‐Jun , Jiao, Niandong , Yin, Ziying , Shi, Yu

Mayo Clinic

International Journal of Surgery | December 11, 2025 | Volume: 112 | Issue: 3 | Pages: 6859-6871

10.1097/js9.0000000000004199 | PMID 41376349 Get It

Background: Accurate characterization of tumor stiffness and adhesion is crucial when surgically resecting meningiomas. Currently, such determinations are difficult to ascertain through standard preoperative imaging diagnostics and clinical experience. Herein, we explored magnetic resonance elastography (MRE) as a means of assessing these parameters and thereby improving neurosurgical resections. Methods: This prospective study of 193 patients with meningiomas involved three distinct patient subsets (cohort 1, 88 [2017–2021]; cohort 2, 55 [2022–2023]; cohort 3, 50 [2023–2024]. We analyzed preoperatively obtained MRE data on meningioma stiffness (cohorts 1 and 2) and adhesion (cohort 2) for accuracy, while matching subjects with or without MRE studies (cohort 3, 1:1 ratio) to define the role of preoperative MRE in improving operative outcomes. Results: Areas under the curve (AUCs) for MRE in gauging meningioma stiffness and adhesion were 0.87 and 0.89, respectively. Both parameters significantly surpassed empiric predictions of stiffness and adhesion rendered by surgeons and radiologists, based on routine magnetic resonance imaging (MRI). MRE-determined stiffness measures independently correlated with prolonged resection duration, whereas MRE-assessed adhesion showed independent associations with increased blood loss, longer duration of tumor resection, and higher risk of pial injury. Ultimately, results based on cohort 3 demonstrated that MRE has great potential in this setting to improve neurosurgical procedures by significantly reducing intraoperative bleeding, resection duration, and risks of pial injury. Conclusion: MRE is a promising, noninvasive tool for accurately assessing meningioma stiffness and adhesion, standing to improve the precision and safety of needed surgical intervention.
Ultrasound Localization Microscopy to Assess the Intrarenal Microvasculature in Autosomal Dominant Polycystic Kidney Disease
Huang, Chengwu , Abd-Elfattah, Ahmed Saleh , DeRuiter, Ryan M. , Zhang, Nathan , Knoll, Kate M , Petersen, Kendra E. , Wu, Tao , Hogan, Marie C. , Eirin, Alfonso , Lerman, Lilach O. , Irazabal, María V. , Abdelfattah, Ahmed , Zhang, Youwen, Hogan, Marie C , Eirin, Alfonso , Lerman, Lilach O , Irazabal, Maria V , Huang, Chengwu , DeRuiter, Ryan , Petersen, Kendra E , Zhang, Nathan , Zhang, Youwen , Chen, Shigao

Mayo Clinic

Journal of the American Society of Nephrology | December 9, 2025 | Volume: 37 | Issue: 6 | Pages: 1221-1236

10.1681/asn.0000000968 | PMID 41563237 Get It

Key Points The kidney microvasculature was quantified reliably in human autosomal dominant polycystic kidney disease early on, using super-resolution ultrasound localization microscopy. Microvascular parameters correlated with structural and functional indices, constituting promising biomarkers to evaluate noncystic parenchyma. Microvascular parameters may serve to assess disease severity and monitor progression from the early stages of the disease. Background In vitro studies in individuals with autosomal dominant polycystic kidney disease (ADPKD) have shown extensive intrarenal microvascular remodeling. However, analyses have been limited to the time of kidney failure because of the invasive nature of current methodologies to assess the intrarenal microvasculature. We hypothesized that super-resolution ultrasound microvascular imaging, known as ultrasound localization microscopy, enabled by high-framerate ultrasound imaging and microbubble localization and tracking postprocessing techniques, would safely, reliably, and reproducibly assess the intrarenal microvasculature in individuals with ADPKD at an early stage of the disease. Methods We prospectively enrolled young (<40 years of age), well-characterized, early-stage (eGFR >90 ml/min per 1.73 m 2 ) individuals with ADPKD, and sex–age 1:1 matched controls ( n =17 each) and assessed the intrarenal microvasculature using ultrasound localization microscopy. We determined the intersonographer reliability, intraobserver repeatability, and interobserver reproducibility of microvascular parameters in both groups, and the day-to-day variability in the control group. Microvascular parameters were correlated with structural (total kidney volume) and functional (eGFR) markers in individuals with ADPKD. Results Ultrasound localization microscopy provided a super-resolved map of the intrarenal microvasculature in ADPKD and matched controls. Intrarenal microvascular parameters ( e.g ., vessel density) were quantified in a safe, reliable (intraclass correlation coefficients, 0.96; 95% confidence interval, 0.91 to 0.98), reproducible (intraclass correlation coefficient, 0.96; 95% confidence interval, 0.93 to 0.98), and repeatable (coefficient of variations, 3.6%) manner. In control individuals, the day-to-day variability of most parameters was low, with coefficient of variation ranging from 1.8% to 10.7%. Microvascular parameters differed in individuals with ADPKD compared with controls, despite preserved eGFR. Interestingly, cortical vessel density and its derived perfusion correlated directly with eGFR, whereas tortuosity indices presented an inverse correlation. Conclusions Ultrasound localization microscopy provided a safe and reliable in vivo assessment of the human intrarenal microvasculature.
Diagnostic Performance and Interpreter Experience of 1-Hour Versus 3-Hour 99m Tc-HMDP Cardiac Amyloid Radionuclide Imaging: A Prospective, Blinded Comparison
Tersalvi, Gregorio , Carey, Patricia , Garmany, Armin , Scott, Christopher G. , Maldonado, Francisco J., Krüger, Leandi , Hruska, Carrie B. , Johnson, Geoffrey B. , Jouni, Hayan, Rodriguez‐Porcel, Martin , Askew, J. Wells , Bois, John P. , Young, Kathleen A. , Anavekar, Nandan S., Grogan, Martha , Homb, Andrew, Zhang, Jun , Kruger, Livia F , Hruska, Carrie B , Johnson, Geoffrey B , Rodriguez-Porcel, Martin G., Askew, J Wells , Young, Kathleen , Grogan, Martha , Dispenzieri, Angela , Chareonthaitawee, Panithaya , Homb, Andrew C, AbouEzzeddine, Omar F , Scott, Christopher , Tersalvi, Gregorio , Carey, Patricia , Zhang, Jun , Maldonado, Francisco J., Dispenzieri, Angela , Chareonthaitawee, Panithaya , AbouEzzeddine, Omar F.

Mayo Clinic

Circulation: Cardiovascular Imaging | December 8, 2025 | Volume: 19 | Issue: 1 | Pages: No page available

10.1161/circimaging.125.018745 | PMID 41355666 Get It

BACKGROUND: Guidelines recommend 3-hour cardiac amyloid radionuclide imaging (CARI) for transthyretin amyloid cardiomyopathy. Citing rapid blood clearance of 99m Tc-hydroxymethylene-diphosphonate (HMDP) and efficient laboratory throughput, 1-hour imaging is increasingly practiced despite limited supporting evidence. We sought to compare diagnostic performance and interpreter experience of 1-hour versus 3-hour HMDP-CARI. METHODS: Consecutive patients with suspected transthyretin amyloid cardiomyopathy (n=114) underwent both 1-hour and 3-hour HMDP single photon emission computed tomography (CT)/CT. Two cardiologist-radiologist reader teams, blinded to imaging timepoint (1 versus 3 hours), assessed overall interpretation, single photon emission CT–based Perugini grade, interpretation difficulty, interpreter confidence, and need for CT-fused images for anatomic localization. Discordant, equivocal, and difficult cases were arbitrated by a third tie-breaking team. The myocardial-to-blood-pool radiotracer uptake ratio (3-dimensional Score) was measured as a surrogate of contrast resolution. RESULTS: Interinterpreter agreement was high at both time points (κ≥0.81), with more cases requiring arbitration at 3 hours versus 1 hour (22% versus 13%; P =0.049). Overall interpretation and Perugini grades were concordant between time points in 111/114 (97%) and 106/114 (93%) patients, respectively. Three patients (3%) were negative at 1 hour but equivocal at 3 hours, all of which were clinically ruled out for transthyretin amyloid cardiomyopathy. Interpreter confidence was comparable at both timepoints (97% versus 95%; P =0.317). Compared with 3-hour imaging, contrast resolution was inferior (lower 3-dimensional score, P <0.001) and CT fusion was more frequently needed (57% versus 31%, P <0.001) at 1-hour imaging. CONCLUSIONS: In a prospective, blinded comparison of 1-hour versus 3-hour HMDP-CARI, diagnostic performance and interpreter experience were similar, with readers requesting CT fusion more frequently at 1 hour to optimize myocardial-to-blood pool discrimination.
Multiscale Segmentation-Guided Diffusion Model for CBCT-to-CT Synthesis
Guo, Yike, Luo, Yi , Hooshangnejad, Hamed , Zhang, Rui , Feng, Xue , Chen, Quan , Ngwa, Wilfred , Ding, Kai , Chen, Quan , Feng, Xue , Ding, Kai , Guo, Yike

Mayo Clinic

Life | December 8, 2025 | Volume: 15 | Issue: 12 | Pages: 1871

10.3390/life15121871 | PMID 41465810 Get It

To improve synthetic CT (sCT) generation from cone-beam CT (CBCT) in radiotherapy, we propose a multiscale segmentation-guided diffusion framework. The proposed model integrates anatomical priors across multiple spatial resolutions through a segmentation mask pyramid and introduces a scale-specific loss function to guide learning at each level. When evaluated on the SynthRAD2023 brain dataset, our model achieves a mean absolute error (MAE) of 61.82 HU, a peak signal-to-noise ratio (PSNR) of 32.05 dB, and a structural similarity index (SSIM) of 0.90, outperforming baseline models. These results suggest that multiscale anatomical guidance can improve the fidelity and anatomical consistency of sCT images, thus facilitating high-quality CBCT-to-CT translation in radiotherapy applications.
Cyst-X: AI-Powered Pancreatic Cancer Risk Prediction from Multicenter MRI in Centralized and Federated Learning
Bağcı, Ulaş , Pan, Hongyi , Keleş, Elif , Seyithanoğlu, Deniz, Zhang, Zheyuan , Aktaş, Halil , Bejar, Andrea , Hong, Ziliang , Taktak, Yavuz , Kartal, Gulbiz, Cebeci, Timurhan , Gonzalez, Maria , Zhao, Lili , Agarunov, Emil, Salanitri, Federica Proietto , Tiwari, Pallavi , Bruno, Marco J. , Huang, Chenchang, Bolan, Candice W. , Gonda, Tamas A. , Miller, Frank, Keswani, Rajesh N. , Zhao, Lili , Bagci, Ulas , Durak, Görkem , Medetalibeyoğlu, Alpay , Ertürk, Şükrü Mehmet , Gonzalez, Maria, Velichko, Yury , Spampinato, Concetto , Tiwari, Pallavi , Xu, Ziyue , Jambawalikar, Sachin , Schoots, Ivo G. , Huang, Chenchang, Wallace, Michael B.

Mayo Clinic

No container title available | December 8, 2025 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-7236860/v1 Get It

Abstract Pancreatic cancer, projected to become the second-deadliest malignancy in Western societies by 2030, requires urgent innovations in early detection and risk stratification. Intraductal papillary mucinous neoplasms (IPMNs) represent critical precursor lesions, but current clinical guidelines demonstrate suboptimal accuracy in malignancy prediction, leading to either unnecessary surgeries or missed opportunities for early intervention. In this paper, we present Cyst-X, an artificial intelligence (AI) framework that accurately predicts IPMN malignant transformation using multicenter magnetic resonance imaging (MRI) data. Unlike most previous approaches that rely on computed tomography (CT), our method capitalizes on the superior soft tissue contrast of MRI, allowing for more precise identification of subtle imaging biomarkers. We developed and validated deep learning models on 723 T1-weighted and 738 T2-weighted MRI scans from 764 patients among seven international institutions, demonstrating significantly superior performance (AUC=0.82) compared to current clinical (Kyoto) guidelines (AUC=0.75) and expert radiologists. AI-based imaging features correlate strongly with clinically recognized malignancy markers, providing potential biologically relevant insights. This approach holds promise to significantly refine clinical decision-making, reduce unnecessary surgeries, and better identify high-risk IPMN patients for timely intervention. Our approach integrates a novel pancreas segmentation network with robust classification models that identify subtle imaging biomarkers associated with malignancy risk. Importantly, we demonstrate that these models retain high performance in a privacy-preserving federated learning setting, where institutions collaboratively train AI models without exchanging patient data to address key regulatory and ethical barriers. We publicly release the Cyst-X dataset--the first large-scale, multi-center pancreatic cyst MRI collection--to accelerate research in this field. This study addresses a critical clinical need while establishing technical foundations for privacy-preserving AI in radiology that could transform pancreatic cancer management through earlier intervention and reduced unnecessary procedures. The dataset can be accessed at https://osf.io/74vfs/, and the source code for our deep learning segmentation and classification models is available at https://github.com/NUBagciLab/Cyst-X.
Proinflammatory GSDMD activation in live macrophages and DLBCL cells marks cognate interactions and better prognosis
Kong, Xue, Xu‐Monette, Zijun Y. , Xu, Zhenming , Zhao, Xiaoxian , Nunns, Harry , Visco, Carlo , Tzankov, Alexandar , Dybkær, Karen , Yao, Shuna , Wu, Dehong , Wang, Chang , Pan, Zenggang , Parsons, Benjamin M. , Chiu, April , Tam, Wayne , Zhan, Fenghuang , Bernal‐Mizrachi, Leon , Zu, Youli , Zhang, Shanxiang , Chen, Weina , Au, Qingyan , Merchant, Akil , Bhagat, Govind , Young, Ken H. , Visco, Carlo , Dybkaer, Karen , Wang, Chang , Xu, Alexander M , Pan, Zenggang , Parsons, Benjamin M , Chiu, April , Zhan, Fenghuang , Møller, Michael Boe , Chen, Weina , Merchant, Akil , Bhagat, Govind , Li, Yong , Young, Ken H , Tzankov, Alexandar , Zu, Youli , Xu-Monette, Zijun Y , Hsi, Eric D. , Yan, Hui Min , Au, Kelly, Xu, Alexander M. , Montes‐Moreno, Santiago , Møller, Michael , Li, Yong

Mayo Clinic

Blood Advances | December 5, 2025 | Volume: 10 | Issue: 5 | Pages: 1756-1772

10.1182/bloodadvances.2025017643 | PMID 41346287 Get It

Abstract Pyroptosis is a form of programmed cell death characterized by the cleavage of the gasdermin (GSDM) family proteins that form pores in the plasma membrane, cell rupture, and the release of proinflammatory cytokines. In this study, we performed immunohistochemistry for cleaved gasdermin D (GSDMD), gasdermin E (GSDME) N-terminus, and gasdermin C (GSDMC) in 2 different cohorts of diffuse large B-cell lymphoma (DLBCL) and analyzed the impact of GSDM expression on prognosis and immunity. The results showed frequent cleaved GSDMD (N-terminal) expression. Only cytoplasmic GSDMD N-terminal expression correlated with significantly better patient survival in the 2 cohorts. In contrast, GSDME was mainly expressed in the vascular endothelium, and correlated with significantly adverse prognostic effect. Correlating with the multiplex fluorescent immunohistochemistry results, we found that cytoplasmic GSDMD N-terminal expression was associated with increased CD38+ (activated) M1 macrophages in both cohorts, cognate interactions between live DLBCL cells and activated M1 macrophages (and T cells), and lower PD-1/PD-L1 expression in the analyzed cases. In contrast, T-cell pyroptosis, lymphoma cell-resistance to cell death, and phagocytosis by M2 macrophages were observed in tissues with predominantly nuclear GSDMD N-terminal expression. Bulk gene expression profiling and deconvolution analysis revealed associations of cytoplasmic GSDMD N-terminal expression with downregulation of “Don’t eat me”–signaling genes, upregulation of many RNA genes, decreased frequency of “inflammatory” lymphoma microenvironment subtype, increased frequencies of prognostically favorable cell states and ecotypes, and decreased frequency of T-cell exhaustion state. In summary, this study showed distinct cellular and subcellular patterns of 3 GSDM proteins and their associated immune response phenotypes and prognostic effects, with implications for novel therapeutic strategies for B-cell lymphoma.